Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-421 SC in Treatment Naive HIV-1 Infected Patients
NCT04620304Phase 1Completed
- Sponsor
- United BioPharma
- Start
- Jan 2021
- Primary completion
- May 2022
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of semzuvolimab in human immunodeficiency virus type 1 infection (HIV-1) (3 cohorts), sponsored by United BioPharma. Primary endpoint: Treatment-Emergent Adverse Events at 28 days. Started Jan 2021; status: completed.
02
Drugs
semzuvolimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04620304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620304.